Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
5.17
+0.44 (9.30%)
At close: Apr 1, 2026, 4:00 PM EDT
5.23
+0.06 (1.16%)
After-hours: Apr 1, 2026, 7:46 PM EDT
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Atara Biotherapeutics stock have a consensus rating of "Sell" and an average price target of $5.00, which forecasts a -3.29% decrease in the stock price over the next year. The lowest target is $4.00 and the highest is $6.00.
Price Target: $5.00 (-3.29%)
Analyst Consensus: Sell
* Price targets were last updated on Jan 21, 2026.
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 0 | 0 | 0 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 5 | 4 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Freedom Broker | Freedom Broker | Strong Buy → Strong Sell Downgrades $16 → $4 | Strong Buy → Strong Sell | Downgrades | $16 → $4 | -22.63% | Jan 21, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $25 → $6 | Strong Buy → Hold | Downgrades | $25 → $6 | +16.05% | Jan 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 → $25 | Strong Buy | Maintains | $17 → $25 | +383.56% | Dec 19, 2025 |
| Freedom Broker | Freedom Broker | Strong Sell Maintains $13 → $16 | Strong Sell | Maintains | $13 → $16 | +209.48% | Jul 28, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +228.82% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
43.76M
from 120.77M
Decreased by -63.77%
Revenue Next Year
35.01M
from 43.76M
Decreased by -19.99%
EPS This Year
-0.10
from 2.57
EPS Next Year
-0.41
from -0.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 76.7M | 70.4M | |||
| Avg | 43.8M | 35.0M | |||
| Low | 7.1M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -36.5% | 60.8% | |||
| Avg | -63.8% | -20.0% | |||
| Low | -94.2% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.91 | -0.07 | |||
| Avg | -0.10 | -0.41 | |||
| Low | -0.71 | -0.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -64.5% | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.